Skip to Content

eSURFACE 1 and reSURFACE 2: Biological therapy improves psoriasis and CVD

As a fact, cardiovascular diseases (CVD) are highly prevalent in patients with psoriasis, and hence Professor Nehal Mehta and his team have been using this as a model to study inflammatory atherogenesis. In this MEDtalk, he presents very interesting results from the reSURFACE 1 and 2 regarding the association between psoriasis and CVD and how both conditions improve following biological therapy with tildrakizumab.

Nehal Mehta

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top